Form 4: KEQU CEO Sells Shares Under 10b5-1 Plan

KEWAUNEE SCIENTIFIC CORP's President and CEO, Thomas David Hull III, sold 1,000 shares of common stock for $39 per share on December 17, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Thomas David Hull III, who serves as Director, President, and CEO of KEWAUNEE SCIENTIFIC CORP /DE/, executed a sale of common stock.
• The transaction occurred on December 17, 2025.
• A total of 1,000 shares of common stock were disposed of at a price of $39 per share.
• The total value of the shares sold was $39,000.
• Following this transaction, Thomas David Hull III beneficially owns 37,719 shares of common stock.
• The sale was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The sale of shares by the CEO was conducted under a pre-arranged Rule 10b5-1 plan, which typically indicates a scheduled liquidity event rather than a reaction to new material non-public information. This makes the transaction largely neutral in terms of immediate sentiment, though any insider sale can be viewed with slight caution.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1(c) plan, indicating a scheduled transaction rather than a discretionary sale based on new, potentially negative, information.

Negatives

• An insider sale, even if pre-planned, reduces the executive's direct ownership in the company, which can sometimes be perceived with slight caution by the market.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sale of 1,000 shares of common stock by Thomas David Hull III, President, CEO, and Director, to the open market.

Stakeholder Impact

• Shareholders: The sale by a key executive could be perceived as a slight negative, though mitigated by the 10b5-1 plan, as it does not signal a lack of confidence in the company's immediate future.

Key Dates

Recommendation

The Form 4 filing reports a routine, pre-scheduled sale of a relatively small number of shares by the CEO under a 10b5-1 plan. This transaction does not provide new fundamental information about the company's operations or future prospects that would warrant a change in investment recommendation. Investors should continue to hold based on the company's underlying business performance rather than this specific insider transaction.

Keywords

KEQU, Kewaunee Scientific, Insider Trading, Form 4, Stock Sale, CEO, Director, 10b5-1 Plan